Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data
- PMID: 20043295
- DOI: 10.1002/pst.400
Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data
Erratum in
- Pharm Stat. 2011 Mar-Apr;10(2):187-9
Abstract
Pharmacokinetic (PK) data often contain concentration measurements below the quantification limit (BQL). While specific values cannot be assigned to these observations, nevertheless these observed BQL data are informative and generally known to be lower than the lower limit of quantification (LLQ). Setting BQLs as missing data violates the usual missing at random (MAR) assumption applied to the statistical methods, and therefore leads to biased or less precise parameter estimation. By definition, these data lie within the interval [0, LLQ], and can be considered as censored observations. Statistical methods that handle censored data, such as maximum likelihood and Bayesian methods, are thus useful in the modelling of such data sets. The main aim of this work was to investigate the impact of the amount of BQL observations on the bias and precision of parameter estimates in population PK models (non-linear mixed effects models in general) under maximum likelihood method as implemented in SAS and NONMEM, and a Bayesian approach using Markov chain Monte Carlo (MCMC) as applied in WinBUGS. A second aim was to compare these different methods in dealing with BQL or censored data in a practical situation. The evaluation was illustrated by simulation based on a simple PK model, where a number of data sets were simulated from a one-compartment first-order elimination PK model. Several quantification limits were applied to each of the simulated data to generate data sets with certain amounts of BQL data. The average percentage of BQL ranged from 25% to 75%. Their influence on the bias and precision of all population PK model parameters such as clearance and volume distribution under each estimation approach was explored and compared.
Copyright © 2009 John Wiley & Sons, Ltd.
Similar articles
-
[Meta-analysis of the Italian studies on short-term effects of air pollution].Epidemiol Prev. 2001 Mar-Apr;25(2 Suppl):1-71. Epidemiol Prev. 2001. PMID: 11515188 Italian.
-
Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.Pharm Stat. 2009 Apr-Jun;8(2):98-112. doi: 10.1002/pst.336. Pharm Stat. 2009. PMID: 18481279
-
A Bayesian approach for PK/PD modeling with PD data below limit of quantification.J Biopharm Stat. 2012;22(6):1220-43. doi: 10.1080/10543406.2011.585441. J Biopharm Stat. 2012. PMID: 23075019
-
A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.Curr Clin Pharmacol. 2018;13(4):216-235. doi: 10.2174/1574884713666181025144845. Curr Clin Pharmacol. 2018. PMID: 30360723 Review.
-
Estimating the prevalence of infections in vector populations using pools of samples.Med Vet Entomol. 2012 Dec;26(4):361-71. doi: 10.1111/j.1365-2915.2012.01015.x. Epub 2012 Apr 8. Med Vet Entomol. 2012. PMID: 22486773 Review.
Cited by
-
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):211-221. doi: 10.1002/psp4.12075. Epub 2016 Apr 14. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27104090 Free PMC article.
-
Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.CPT Pharmacometrics Syst Pharmacol. 2013 Jul 17;2(7):e56. doi: 10.1038/psp.2013.31. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 23863865 Free PMC article.
-
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.Antimicrob Agents Chemother. 2011 Nov;55(11):5306-13. doi: 10.1128/AAC.05136-11. Epub 2011 Aug 29. Antimicrob Agents Chemother. 2011. PMID: 21876056 Free PMC article. Clinical Trial.
-
Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.Clin Pharmacokinet. 2022 Feb;61(2):321-333. doi: 10.1007/s40262-021-01068-0. Epub 2021 Oct 7. Clin Pharmacokinet. 2022. PMID: 34617261 Free PMC article. Clinical Trial.
-
Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens.PLoS One. 2020 Mar 5;15(3):e0229873. doi: 10.1371/journal.pone.0229873. eCollection 2020. PLoS One. 2020. PMID: 32134971 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources